Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912

Authors

• Tait D. Shanafelt, Stanford University School of Medicine, Stanford, California, United States.
• Xin Victoria Wang, Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, United States.
• Curtis A. Hanson, Mayo Clinic, Rochester, Minnesota, United States.
• Elisabeth Paietta, Montefiore Medical Center, Bronx, New York, United States.
• Susan M. O'Brien, Chao Family Comprehensive Cancer Center at UC Irvine Medical Center, Orange, California, United States.
• Jacqueline Claudia Barrientos, Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida, United States.
• Diane F. Jelinek, Mayo Clinic, Scottsdale, Arizona, United States.
• Esteban Braggio, Mayo Clinic Arizona, Scottsdale, Arizona, United States.
• Jose F. Leis, Mayo Clinic, Phoenix, Arizona, United States.
• Cong Zhang, Kaiser Permanente NCORP, Fresno, California, United States.
• Paul M. Barr, Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States.
• Amanda F. Cashen, Washington University School of Medicine, St Louis, Missouri, United States.
• Anthony R. Mato, Memorial Sloan Kettering Cancer Center, United States.
• Avina K. Singh, Minnesota Oncology, Burnsville, Minnesota, United States.
• Michael Mullane, Advocate Health - MidwestFollow
• Richard F. Little, National Cancer Institute, Bethesda, Maryland, United States.
• Harry P. Erba, Duke University, Durham, North Carolina, United States.
• Richard M. Stone, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
• Mark R. Litzow, Mayo Clinic, Rochester, Minnesota, United States.
• Martin S. Tallman, Memorial Sloan Kettering Cancer Center, United States.
• Neil E. Kay, Mayo Clinic, Rochester, Minnesota, United States.

Recommended Citation

Shanafelt TD, Wang XV, Hanson CA, et al. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv. 2025;9(1):224-228. doi:10.1182/bloodadvances.2024013474

Affiliations

Aurora Health Care, Mount Pleasant

Type

Article

PubMed ID

39163612